Below are the top biotechnology stocks on the NYSE and the NASDAQ in terms of revenue estimates.Amgen Inc (NASDAQ: AMGN) is expected to generate $15.10 billion of revenue in the current year. Analysts at Argus upgraded AMGN from “hold” to “buy.”
Gilead Sciences Inc (NASDAQ: GILD is likely to generate $8.06 billion of revenue in the current year. GILD’s shares dipped 23.78% over the past 52 weeks, while the S&P 500 index gained 13.78% in the same period.
Genzyme Corporation (NASDAQ: GENZ) may generate $4.99 billion of revenue in this year. GENZ’s PEG ratio is 1.06.
The revenue estimates for Biogen Idec Inc (NASDAQ: BIIB) for the current year is $4.52 billion. BIIB’s PEG ratio is 1.12.
No comments:
Post a Comment